SAGE Therapeutics, Inc.
(NASDAQ : SAGE)

( )
SAGE After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
Loading SAGE News...
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc.
-0.14%10.719.9%$277.20m
PRGOPerrigo Co. Plc
0.46%68.454.8%$176.72m
SHPGShire PLC Sponsored ADR
0.58%174.150.3%$168.21m
MDCOMedicines Company
0.59%49.6522.6%$128.27m
ENDPEndo International Plc
-2.85%9.878.9%$124.21m
UTHRUnited Therapeutics Corporation
0.79%139.3711.5%$96.01m
JAZZJazz Pharmaceuticals Plc
-0.43%142.341.9%$85.38m
MNKMallinckrodt Plc
-3.45%42.5312.8%$84.56m
PRXLPAREXEL International Corporation
1.22%62.006.7%$68.50m
PCRXPacira Pharmaceuticals, Inc.
3.00%48.1516.9%$64.12m
ICPTIntercept Pharmaceuticals, Inc.
0.21%116.2522.8%$54.02m
PTLAPortola Pharmaceuticals, Inc.
1.40%38.5110.3%$49.77m
HZNPHorizon Pharma plc
0.21%14.529.7%$45.62m
GWPHGW Pharmaceuticals PLC Sponsored ADR
0.37%119.509.9%$40.74m
ICLRICON Plc
0.39%78.082.8%$37.95m

Company Profile

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company engages in the development and commercialization of novel medicines to treat central nervous system disorders. Its product candidate includes SAGE-547, which is in clinical development for super-refractory status epileptics; SAGE-217; and SAGE-689, which are in IND-enabling toxicology and safety pharmacology testing. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.